S
Silvio Danese
Researcher at Humanitas University
Publications - 1184
Citations - 47449
Silvio Danese is an academic researcher from Humanitas University. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 90, co-authored 893 publications receiving 35801 citations. Previous affiliations of Silvio Danese include The Catholic University of America & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
The Role of JAM-A in Inflammatory Bowel Disease: Unrevealing the Ties That Bind
Stefania Vetrano,Silvio Danese +1 more
TL;DR: The role of JAM‐A is focused on in controlling mucosal homeostasis by regulating the integrity and permeability of epithelial barrier function, which is important in the pathogenesis of inflammatory bowel disease.
Journal ArticleDOI
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?
TL;DR: The current evidence on efficacy and safety of some natural products that are believed to be effective in inflammatory bowel disease are reviewed.
Journal ArticleDOI
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents
Walter Reinisch,Walter Reinisch,Jørgen Jahnsen,Jørgen Jahnsen,Stefan Schreiber,Silvio Danese,Julián Panés,Alejandro Balsa,Won Park,Ji Soo Kim,Jee Un Lee,Dae Hyun Yoo +11 more
TL;DR: This study has demonstrated that ADAs and NAbs against CT-P13 and RP are cross-reactive, indicating that CT-NAb and RP share immunodominant epitopes.
Journal ArticleDOI
The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches.
TL;DR: The discovery of peculiar inflammatory bowel disease-associated microbial strains will not only shed new light oninflammatory bowel disease aetiogenesis, they may also support the development of novel therapeutic strategies not merely treating symptoms, but precisely counteracting the primary cause of chronic intestinal inflammation.
Journal ArticleDOI
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Gionata Fiorino,Flavio Caprioli,Marco Daperno,Filippo Mocciaro,Mariabeatrice Principi,Angelo Viscido,Massimo Fantini,Ambrogio Orlando,Claudio Papi,Vito Annese,Silvio Danese,Maurizio Vecchi,Fernando Rizzello,Alessandro Armuzzi +13 more
TL;DR: The Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars.